1. 1. Lundell LR, Dent J, Bennett JR, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-180.
2. 2. Ariizumi K, Ohara S, Koike T, Inomata Y, Iijima K, Sekine H, Noguchi M, Sugiyama K, Eda Y, Kayaba S, Kawamura M, Shimosegawa T: Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J Gastroenterol Hepatol 2006; 21: 1428-1434.
3. 3. Kinoshita Y, Miwa H, Kasugai K: Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis ―a phase III, multicenter, randomized, double-blind trial-. Nihon Shokakibyo Gakkai Zasshi 2013; 110: 1428-1438 (in Japanese).
4. 4. Mizuno H, Matsuhashi N, Sakaguchi M, Inoue S, Nakada K, Higuchi K, Haruma K, Joh T: Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in Japan. J Clin Biochem Nutr 2015; 57: 233-238.
5. 5. Iwakiri K, Hayashi Y, Kotoyori M, Tanaka Y, Kawakami A, Sakamoto C, Holloway R: Transient lower esophageal sphincter relaxations (TLESRs) are major mechanism of gastroesophageal reflux but are not the cause of reflux disease. Dig Dis Sci 2005; 50: 1072-1077.